
Metoprolol Succinate (25mg) + Telmisartan (40mg)
Active composition
+1 more active ingredient
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Medical applications
Eritel B 40mg/25mg Tablet PR is a combination antihypertensive medication containing Telmisartan 40mg and Metoprolol Succinate 25mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and decreased myocardial oxygen demand. This combination is indicated for the treatment of hypertension, providing complementary mechanisms to achieve effective blood pressure control in patients who require dual therapy. Eritel B 40mg/25mg Tablet PR is formulated as a prolonged-release tablet to ensure consistent plasma concentrations and improve patient compliance with once-daily dosing. It is contraindicated in patients with severe bradycardia, cardiogenic shock, or known hypersensitivity to either component. Caution is advised in patients with diabetes, renal or hepatic impairment, and those with a history of bronchospastic diseases. Regular monitoring of blood pressure, heart rate, renal function, and electrolytes is recommended during therapy to optimize treatment outcomes and minimize adverse effects.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Eritel B 40mg/25mg Tablet PR is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Eritel B 40mg/25mg Tablet PR is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Medical Advice
Eritel B 40mg/25mg Tablet PR is safe to use in patients with kidney disease. No dose adjustment of Eritel B 40mg/25mg Tablet PR is recommended.
Exercise Caution
Eritel B 40mg/25mg Tablet PR may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Eritel B 40mg/25mg Tablet PR should be used with caution in patients with liver disease. Dose adjustment of Eritel B 40mg/25mg Tablet PR may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Eritel B 40mg/25mg Tablet PR

Telmisartan (40mg) + Metoprolol Succinate (25mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Medical applications
Eritel B 40mg/25mg Tablet PR is a combination antihypertensive medication containing Telmisartan 40mg and Metoprolol Succinate 25mg. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, which leads to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and decreased myocardial oxygen demand. This combination is indicated for the treatment of hypertension, providing complementary mechanisms to achieve effective blood pressure control in patients who require dual therapy. Eritel B 40mg/25mg Tablet PR is formulated as a prolonged-release tablet to ensure consistent plasma concentrations and improve patient compliance with once-daily dosing. It is contraindicated in patients with severe bradycardia, cardiogenic shock, or known hypersensitivity to either component. Caution is advised in patients with diabetes, renal or hepatic impairment, and those with a history of bronchospastic diseases. Regular monitoring of blood pressure, heart rate, renal function, and electrolytes is recommended during therapy to optimize treatment outcomes and minimize adverse effects.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Eritel B 40mg/25mg Tablet PR is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Eritel B 40mg/25mg Tablet PR is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Medical Advice
Eritel B 40mg/25mg Tablet PR is safe to use in patients with kidney disease. No dose adjustment of Eritel B 40mg/25mg Tablet PR is recommended.
Exercise Caution
Eritel B 40mg/25mg Tablet PR may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Eritel B 40mg/25mg Tablet PR should be used with caution in patients with liver disease. Dose adjustment of Eritel B 40mg/25mg Tablet PR may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Eritel B 40mg/25mg Tablet PR















